gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with arginyl-glycyl-aspartic acid in 4 studies
| Studies (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Trials (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Recent Studies (post-2010) (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Studies (arginyl-glycyl-aspartic acid) | Trials (arginyl-glycyl-aspartic acid) | Recent Studies (post-2010) (arginyl-glycyl-aspartic acid) |
|---|---|---|---|---|---|
| 638 | 31 | 243 | 4,556 | 17 | 1,799 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; Ha, S; Jung, JC; Kim, TJ; Lee, JJ; Oh, C; Park, JA; Yu, DY | 1 |
| Gu, YJ; Jin, J; Lam, MH; Wong, WT; Xu, Z; Zhang, Y | 1 |
| Chang, Y; Kim, JY; Kim, KM; Kim, TJ; Ko, IO; Lee, YJ; Lim, SM; Park, JA | 1 |
| Chen, S; Li, H; Liu, M; Ren, L; Ye, C; Zhang, Z; Zhou, X | 1 |
4 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent.
Topics: Animals; Cell Line; Cell Survival; Chickens; Contrast Media; Genes, ras; Heterocyclic Compounds; Integrin alphaVbeta3; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Mice; Mice, Transgenic; Neoplasm Transplantation; Oligopeptides; Organometallic Compounds; Protein Binding | 2008 |
Upconversion nanoparticles conjugated with Gd(3+) -DOTA and RGD for targeted dual-modality imaging of brain tumor xenografts.
Topics: Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Endocytosis; Heterocyclic Compounds; Humans; Magnetic Phenomena; Magnetic Resonance Imaging; Mice, Inbred BALB C; Mice, Nude; Multimodal Imaging; Nanoparticles; Oligopeptides; Organometallic Compounds; Spectrophotometry, Atomic; Surface Properties; Xenograft Model Antitumor Assays | 2013 |
Improved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptide.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Contrast Media; Cycloparaffins; Female; Gadolinium; Heterocyclic Compounds; Humans; Integrins; Kidney; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Oligopeptides; Organometallic Compounds; Protein Binding; Urinary Bladder | 2014 |
MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Carriers; Fluorescent Dyes; Heterocyclic Compounds; Humans; Liposomes; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Nanostructures; Neoplasms; Oligopeptides; Organometallic Compounds; Paclitaxel; Polyethylene Glycols; Radiography; Transplantation, Heterologous | 2015 |